≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Muscle wasting and atrophy, not elsewhere classified

DOID EFO Endpoint Browser PheWeb

M13_MUSCLEATROPH

muscular disease: Acquired, familial, and congenital disorders of skeletal muscle and smooth muscle.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M62.5
  • Hospital discharge: ICD-9 — 7282A
  • Hospital discharge: ICD-8 — 7331
  • Cause of death: ICD-10 — M62.5
  • Cause of death: ICD-9 — 7282A
  • Cause of death: ICD-8 — 7331

2 out of 7 registries used, show all original rules.

222

4. Check minimum number of events

None

222

5. Include endpoints

None

222

6. Filter based on genotype QC (FinnGen only)

217

Control definitions (FinnGen only)

Control exclude
M13_SOFTTISSUE

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M62
Name in latin
Atrophia et degeneratio musculi non alibi classificatae

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1539 650 867
Only index persons 1277 562 715
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.02
Only index persons 0.02 0.02 0.03
Median age at first event (years)
Whole population 58.20 59.33 57.32
Only index persons 57.86 58.68 57.22

-FinnGen-

Key figures

All Female Male
Number of individuals 217 100 117
Unadjusted period prevalence (%) 0.05 0.04 0.05
Median age at first event (years) 57.86 54.31 60.89

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
222
Matched controls
2220
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M62.5
ICD-10 Finland
Muscle wasting and atrophy, not elsewhere classified
+∞
240.7
185
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
12.7
29.1
30
27
G72.9
ICD-10 Finland
Myopathy, unspecified
93.5
23.2
25
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.1
20.2
39
75
73310
ICD-8 Finland
Other diseases of muscle, tendon and fascia, Muscular atrophy (idiopathic)
+∞
20.1
19
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.8
20.1
53
135
M79.6
ICD-10 Finland
Pain in limb
3.2
15.7
91
393
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
6.8
14.5
24
39
7282A
ICD-9 Finland
Disorders of muscle, ligament and fascia, Muscular wasting and disuse atrophy, not elsewhere classified
+∞
13.7
13
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
10.4
13.4
26
28
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
6.0
13.4
25
46
M15.9
ICD-10 Finland
Polyarthrosis, unspecified
5.5
12.3
25
50
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
4.1
11.4
35
98
N03AX12
ATC
[U] gabapentin; oral
3.5
11.3
44
146
N02AX02
ATC
tramadol; systemic, rectal
2.6
11.2
104
558
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
19.0
10.9
16
9
L28
ICPC
Limited function/disability (L)
3.1
10.8
55
214
M54.5
ICD-10 Finland
Low back pain
2.6
10.3
80
390
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
4.3
9.6
26
66
M13.9
ICD-10 Finland
Arthritis, unspecified
4.4
9.5
25
62
G12.9
ICD-10 Finland
Spinal muscular atrophy, unspecified
+∞
9.4
9
*
A28
ICPC
Limited function/disability NOS
2.8
9.2
58
252
M48.0
ICD-10 Finland
Spinal stenosis
3.4
9.1
37
125
ACC59
NOMESCO Finland
Decompression and freeing of adhesions of peripheral nerve: other or unspecified
9.1
8.5
17
20
G56.0
ICD-10 Finland
Carpal tunnel syndrome
3.5
8.5
31
98
NXL00
NOMESCO Finland
Biopsy of muscle
+∞
8.4
8
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.7
8.3
55
245
M54.1
ICD-10 Finland
Radiculopathy
7.3
8.3
19
28
TAB00
NOMESCO Finland
Lumbar puncture
6.8
8.2
20
32
M25.5
ICD-10 Finland
Pain in joint
2.5
8.2
65
315
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.8
8.1
47
195
G56.2
ICD-10 Finland
Lesion of ulnar nerve
10.0
7.9
15
16
M75.4
ICD-10 Finland
Impingement syndrome of shoulder
15.8
7.8
12
8
M05BA04
ATC
alendronic acid; oral
3.3
7.4
29
96
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
7.3
7
*
N03AX16
ATC
[U] pregabalin
2.5
7.2
56
268
M17.1
ICD-10 Finland
Other primary gonarthrosis
2.5
7.1
54
256
T84.0
ICD-10 Finland
Mechanical complication of internal joint prosthesis
8.0
7.0
15
20
M16.9
ICD-10 Finland
Coxarthrosis, unspecified
4.0
7.0
20
53
SPAT1229
SPAT
Assessment of need for aid
3.4
7.0
26
83
N06AX21
ATC
duloxetine; oral
3.6
6.9
24
73
G12.2
ICD-10 Finland
Motor neuron disease
17.4
6.8
10
6
L04AX03
ATC
methotrexate; systemic
3.5
6.8
24
74
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.5
6.8
24
74
Z3226
NOMESCO Finland
Physiotherapist
2.6
6.8
46
206
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.3
6.7
68
364
M47.80
ICD-10 Finland
Other spondylosis, multiple sites in spine
7.8
6.5
14
19
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.2
6.5
72
399
NE1BG
NOMESCO Finland
Pelvic, hip and femur MRI examination with high intensity magnet
8.6
6.4
13
16
M19.0
ICD-10 Finland
Primary arthrosis of other joints
3.4
6.3
23
72
M20.1
ICD-10 Finland
Hallux valgus (acquired)
3.4
6.3
23
72
M60.9
ICD-10 Finland
Myositis, unspecified
+∞
6.3
6
*
M60.8
ICD-10 Finland
Other myositis
+∞
6.3
6
*
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
+∞
6.3
6
*
N02BF01
ATC
gabapentin; oral
4.0
6.2
18
48
R4120
NOMESCO Finland
Occupational therapy
4.0
6.2
18
48
TQW40
NOMESCO Finland
Remowal of suture of skin
3.5
6.2
22
68
L19
ICPC
Muscle symptom/complaint NOS
9.0
6.1
12
14

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
132
836
2.43
9.41
7.2
7.5
1.22
1.21
mmol/l
0.41
119
715
123
779
2.30
8.46
6.5
6.6
1.21
1.21
mmol/l
0.00
118
709
89
522
2.18
7.07
3.2
4.0
7.40
7.40
ph
0.02
15
97
115
753
2.09
6.78
4.7
4.5
34.29
35.23
g/l
0.85
105
707
114
745
2.09
6.75
6.1
5.7
—
—
—
0
0
159
1192
2.18
6.36
4.9
3.5
11.78
12.35
mm/h
0.23
150
1085
117
786
2.03
6.28
6.2
5.0
0.60
0.61
e9/l
0.19
110
682
117
787
2.03
6.25
6.2
5.0
0.04
0.04
e9/l
0.82
110
684
118
803
2.00
6.03
6.3
5.1
1.99
1.86
e9/l
0.26
113
719
118
809
1.98
5.84
6.4
5.4
0.19
0.18
e9/l
0.19
113
714
37
165
2.49
5.45
1.2
1.3
206.67
412.22
titre
—
6
36
106
718
1.91
5.28
5.8
5.0
0.67
0.64
%
0.22
101
674
46
233
2.23
5.08
1.7
2.3
—
—
—
0
0
122
876
1.87
4.98
5.6
6.6
11.29
11.63
umol/l
0.17
116
833
52
282
2.10
4.83
2.8
4.0
0.81
0.81
mmol/l
0.11
46
267
107
745
1.84
4.75
5.9
5.0
59.65
57.87
%
0.70
102
706
116
843
1.79
4.35
20.6
14.8
1.41
1.28
inr
0.49
23
241
126
940
1.79
4.31
8.0
9.1
4.43
4.20
e9/l
0.51
117
827
98
681
1.79
4.25
2.2
1.9
103.14
90.92
pmol/l
1.12
60
350
26
112
2.50
4.11
1.4
2.6
—
—
—
0
0
8
10
8.25
4.09
1.1
1.1
—
—
—
0
0
56
331
1.93
4.05
1.9
1.7
916.75
1140.12
nmol/l
1.38
45
245
11
23
4.97
3.92
1.1
1.3
—
—
—
0
0
33
167
2.15
3.62
2.3
1.6
—
—
—
0
0
39
212
2.02
3.56
1.3
1.2
14.30
37.15
iu/ml
1.55
14
66
26
121
2.30
3.48
4.5
7.7
—
—
—
0
0
14
47
3.11
3.48
1.1
1.1
—
3.83
—
0
7
7
10
7.18
3.39
1.6
1.0
—
—
—
0
0
72
491
1.69
3.16
5.1
4.3
—
—
—
0
0
18
74
2.56
3.14
2.7
2.3
—
—
—
0
0
7
12
5.98
3.04
1.1
1.0
—
—
—
0
0
59
390
1.70
2.88
2.8
2.9
7521.08
9939.29
umol/l
0.12
52
329
19
84
2.38
2.86
3.7
3.8
—
—
—
0
0
11
33
3.45
2.85
2.1
2.2
—
—
—
0
0
88
646
1.60
2.85
5.4
3.9
77.37
38.96
ng/l
0.93
64
490
15
60
2.61
2.76
1.7
1.9
—
—
—
0
0
6
10
6.13
2.71
5.2
2.3
13.73
13.17
%
—
6
10
47
299
1.73
2.62
1.4
1.2
0.55
1.05
u/ml
1.49
13
83
37
220
1.82
2.59
8.5
9.2
1.81
1.18
mmol/l
0.48
28
181
73
523
1.59
2.57
4.2
3.1
—
—
—
0
0
29
161
1.92
2.50
2.1
2.0
69.58
180.18
ug/g
2.27
22
128
34
202
1.81
2.39
1.3
1.2
2.81
13.44
u/ml
—
7
76
136
1131
1.52
2.38
5.5
4.1
—
—
—
0
0
8
23
3.57
2.29
1.5
1.4
—
—
—
0
0
77
581
1.50
2.09
3.0
3.6
2.35
2.35
mmol/l
0.05
66
515
37
235
1.69
2.07
2.5
2.4
22.27
22.81
%
0.09
28
205
57
404
1.55
2.06
3.0
2.0
3.15
3.24
mg/l
0.12
51
344
29
173
1.78
2.02
1.5
1.4
—
—
—
0
0
48
329
1.59
2.00
4.0
3.4
4390.50
293.00
ng/l
0.60
40
273
49
339
1.57
1.96
1.9
1.7
1.24
1.47
mg/l
0.35
42
270
31
191
1.72
1.94
7.8
10.0
96.42
95.36
%
1.05
31
186
21
118
1.86
1.77
3.6
3.5
0.55
0.59
%
0.06
11
45
69
525
1.46
1.76
3.1
2.3
54.36
65.60
u/l
0.64
64
485
55
402
1.49
1.71
1.5
1.5
24.51
20.51
nmol/l
0.89
48
338
99
808
1.41
1.71
4.9
3.6
0.00
0.01
estimate
0.50
17
157
26
159
1.72
1.68
1.2
1.6
—
—
—
0
0
21
121
1.81
1.65
8.9
9.1
24.02
24.17
mmol/l
0.04
21
114
51
370
1.49
1.64
1.5
1.8
95000415.95
12658647.15
pmol/l
0.40
40
316
123
1047
1.39
1.64
5.9
5.1
7.12
6.76
mmol/l
0.66
117
978
184
1684
1.54
1.64
21.6
14.3
23.29
26.73
mg/l
0.88
162
1330
7
26
2.75
1.59
1.4
2.9
—
—
—
0
0
41
286
1.53
1.59
1.5
1.5
2.87
2.68
g/l
0.13
22
175
6
140
0.41
1.58
1.3
1.5
—
—
—
0
0
91
740
1.39
1.58
12.3
9.3
0.00
0.00
e9/l
0.18
79
611
10
44
2.33
1.58
1.6
1.5
—
—
—
0
0
21
123
1.78
1.57
3.7
3.6
0.00
0.09
%
—
10
46
8
33
2.48
1.55
1.5
3.0
—
—
—
0
0
55
410
1.45
1.55
5.8
7.2
—
—
—
0
0
5
15
3.38
1.53
1.6
3.3
—
—
—
0
0
23
140
1.72
1.52
5.8
3.6
—
—
—
0
0
17
94
1.88
1.52
2.2
2.6
—
—
—
0
0
13
65
2.06
1.52
8.2
12.3
0.88
0.91
%
0.08
13
60
20
117
1.78
1.51
3.4
3.7
0.00
0.02
%
—
9
43
17
95
1.85
1.47
1.2
1.2
—
—
—
0
0
22
134
1.71
1.45
3.7
3.6
1.00
0.82
%
0.16
12
57
31
207
1.58
1.45
1.5
1.3
—
—
—
0
0
6
22
2.77
1.44
1.7
1.3
—
—
—
0
0
47
620
0.69
1.42
3.3
3.0
—
—
—
0
0
9
40
2.30
1.42
2.0
4.3
—
—
—
0
0
7
29
2.46
1.40
4.4
3.1
—
—
—
0
0
13
68
1.97
1.36
8.2
11.7
1.64
1.77
%
0.38
13
62
9
43
2.14
1.32
1.1
1.8
—
—
—
0
0
6
24
2.54
1.31
1.3
2.4
33.17
33.29
pg
—
6
24
6
24
2.54
1.31
1.2
1.3
—
—
—
0
0
10
48
2.13
1.30
3.1
2.8
—
—
—
0
0
11
55
2.05
1.29
2.1
4.2
0.18
0.16
g/l
—
5
24
83
684
1.34
1.28
3.3
2.4
174.50
139.70
ug/l
0.68
77
626
6
25
2.44
1.25
2.7
1.9
1.85
1.56
mmol/l
—
6
25
17
101
1.74
1.24
12.5
14.3
—
—
—
0
0
30
207
1.52
1.23
2.4
2.6
1.87
1.82
%
0.11
24
186
15
86
1.80
1.22
1.3
1.3
—
—
—
0
0
5
19
2.67
1.22
1.0
1.2
—
—
—
0
0
6
26
2.34
1.19
5.0
3.3
—
—
—
0
0
96
816
1.31
1.17
5.1
3.6
0.00
0.00
estimate
-0.00
14
146
0
34
0.00
1.17
0.0
1.5
—
—
—
0
0
5
20
2.53
1.15
3.8
3.8
—
—
—
0
0
5
20
2.53
1.15
2.6
3.2
—
—
—
0
0
0
36
0.00
1.15
0.0
1.3
—
—
—
0
0
45
342
1.40
1.14
2.6
2.9
2.46
2.46
mmol/l
0.06
38
304
7
30
2.38
1.13
3.9
3.9
—
—
—
0
0
57
452
1.35
1.12
3.0
3.0
—
—
—
0
0
5
21
2.41
1.09
3.0
1.8
86.08
88.27
%
—
5
21
7
32
2.23
1.09
5.1
4.2
5.74
4.96
kpa
—
7
32
7
32
2.23
1.09
5.1
4.2
3.16
2.40
mmol/l
—
7
21
7
32
2.23
1.09
5.1
4.2
7.84
8.29
kpa
—
7
32
33
239
1.45
1.09
1.4
1.8
—
—
—
0
0
10
52
1.97
1.08
5.6
15.3
1.17
1.39
mmol/l
—
10
46
7
33
2.16
1.06
1.0
1.7
—
—
—
0
0
7
34
2.09
1.04
4.4
2.8
—
—
—
0
0
7
34
2.09
1.04
4.6
2.8
—
—
—
0
0
60
485
1.32
1.03
2.9
3.0
0.12
0.60
e6/l
3.86
49
369
94
809
1.28
1.02
6.8
4.7
0.00
0.00
estimate
-0.00
15
150
27
191
1.47
1.00
1.7
1.5
—
—
—
0
0
135
1217
1.28
1.00
3.7
3.6
15.22
14.93
pmol/l
0.54
124
1074
79
667
1.29
0.99
2.0
2.1
—
—
—
0
0
23
158
1.51
0.98
3.4
3.9
3.01
1.80
mmol/l
1.01
17
130
23
159
1.50
0.96
5.5
4.8
—
—
—
0
0
0
32
0.00
0.96
0.0
1.5
—
—
—
0
0
0
32
0.00
0.96
0.0
1.4
—
—
—
0
0
73
613
1.28
0.95
3.0
3.5
101.73
211.44
e6/l
0.43
54
448
14
86
1.67
0.93
5.1
4.3
—
—
—
0
0
6
29
2.10
0.90
2.3
2.8
69.77
66.35
%
—
6
29
45
357
1.33
0.88
5.9
4.0
1.01
1.02
kg/l
—
9
53
66
554
1.27
0.86
2.4
2.3
—
—
—
0
0
46
368
1.32
0.85
5.4
3.6
—
—
—
0
0
6
31
1.96
0.85
1.7
1.2
—
—
—
0
0
171
1603
1.29
0.84
5.8
5.8
39.74
40.42
mmol/mol
0.37
159
1477
6
32
1.90
0.82
4.7
4.5
386.67
374.20
umol/l
—
6
25
31
235
1.37
0.81
8.8
6.4
102.87
104.32
mmol/l
1.15
31
235
8
47
1.73
0.81
1.3
1.1
—
—
—
0
0
6
34
1.79
0.77
5.0
2.8
—
—
—
0
0
5
24
2.11
0.75
2.4
2.5
3.20
4.13
e9/l
—
5
24
9
55
1.66
0.74
5.0
4.1
—
—
—
0
0
5
25
2.02
0.73
3.6
2.9
—
—
—
0
0
5
25
2.02
0.73
3.6
2.9
106.40
106.28
mmol/l
—
5
25
5
25
2.02
0.73
3.6
2.9
4.54
4.04
mmol/l
—
5
25
26
197
1.36
0.70
1.2
1.6
—
—
—
0
0
7
42
1.69
0.69
5.1
3.8
7.42
7.42
ph
—
7
34
5
27
1.87
0.69
1.0
1.2
—
—
—
0
0
5
27
1.87
0.69
2.4
2.6
58.20
54.74
%
—
5
27
12
79
1.55
0.64
2.7
4.4
25.22
23.90
mmol/l
0.80
12
79
18
131
1.41
0.61
1.4
1.8
364.56
411.50
nmol/l
0.69
18
122
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
163
1545
1.21
0.57
4.6
4.2
1.99
1.99
mu/l
0.00
151
1374
6
37
1.64
0.56
1.3
1.0
—
—
—
0
0
6
38
1.59
0.54
2.7
3.4
—
—
—
0
0
34
408
0.80
0.52
2.4
2.9
0.76
0.82
ug/l
0.17
22
268
13
95
1.39
0.45
10.8
6.7
25.54
25.17
mmol/l
0.18
13
95
50
438
1.18
0.44
6.0
4.0
0.00
0.00
estimate
-0.00
14
140
0
16
0.00
0.41
0.0
1.1
—
31.69
—
0
16
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
12
88
1.38
0.41
3.3
2.6
0.62
0.68
%
0.47
12
88
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
10
71
1.43
0.40
6.2
3.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
60
539
1.16
0.39
2.9
3.1
28.57
199.56
e6/l
0.82
47
421
58
521
1.15
0.38
5.4
3.7
—
—
—
0
0
16
126
1.29
0.36
1.5
1.4
—
—
—
0
0
12
91
1.34
0.34
3.3
2.7
1.31
1.07
%
0.68
12
91
14
109
1.30
0.34
1.3
1.5
—
—
—
0
0
188
1833
1.17
0.32
12.7
9.9
27.41
26.08
u/l
0.33
183
1758
174
1691
1.13
0.29
4.8
4.5
5.93
6.04
mmol/l
0.56
163
1531
21
178
1.20
0.27
2.0
1.7
—
—
—
0
0
14
113
1.26
0.27
12.5
9.2
94.32
93.76
%
0.28
14
113
114
1087
1.10
0.27
4.1
3.0
71.99
50.80
u/l
0.51
107
1014
49
449
1.12
0.24
1.3
1.4
—
—
—
0
0
20
232
0.85
0.24
1.2
1.3
—
—
—
0
0
56
518
1.11
0.24
2.7
3.2
1316.24
191.78
mg/l
0.42
39
353
5
39
1.29
0.23
1.2
1.1
17.55
24.64
u/l
—
5
33
8
101
0.78
0.21
1.6
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
7.94
—
0
11
0
10
0.00
0.21
0.0
1.6
—
1.49
—
0
10
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
1.01
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
16
138
1.17
0.18
5.7
3.6
—
—
—
0
0
49
457
1.09
0.18
4.5
3.2
—
—
—
0
0
171
1743
0.92
0.17
5.2
4.9
2.81
2.67
mmol/l
1.25
156
1587
59
557
1.08
0.16
3.2
3.7
11.76
11.35
mg/mmol
0.02
39
367
168
1712
0.92
0.16
5.0
4.4
4.72
4.55
mmol/l
1.48
153
1576
167
1699
0.93
0.14
4.8
4.4
1.47
1.45
mmol/l
0.23
152
1546
120
1229
0.95
0.12
4.6
3.9
—
—
—
0
0
181
1787
1.07
0.11
21.1
13.4
—
—
—
0
0
10
115
0.86
0.11
1.2
1.6
—
—
—
0
0
162
1642
0.95
0.09
4.6
4.0
1.32
1.27
mmol/l
0.29
145
1490
17
155
1.10
0.09
9.8
8.9
—
—
—
0
0
70
721
0.96
0.08
4.3
4.9
2.28
2.35
ug/l
0.07
56
643
29
281
1.04
0.02
2.3
2.9
2.00
2.51
e6/l
0.18
18
159
191
1914
0.99
0.00
30.5
20.8
39.10
40.05
%
1.10
175
1772
15
146
1.03
0.00
1.7
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
91.57
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
4.44
—
0
5
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
8
79
1.01
-0.00
1.1
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
4.4
—
—
—
0
0
18
180
1.00
-0.00
1.2
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.6
—
48.64
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
7
74
0.94
-0.00
2.3
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
1611.00
—
0
5
0
5
0.00
-0.00
0.0
2.2
—
1.20
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
50
1.00
-0.00
1.2
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint M13_MUSCLEATROPH and mortality.

Females

Parameter HR [95% CI] p-value
M13_MUSCLEATROPH 2.0 [1.43, 2.8] < 0.001
Birth year 0.994 [0.99, 1.0] 0.168

During the follow-up period (1.1.1998 — 31.12.2019), 100 out of 431 females with M13_MUSCLEATROPH died.

Males

Parameter HR [95% CI] p-value
M13_MUSCLEATROPH 2.175 [1.62, 2.92] < 0.001
Birth year 0.988 [0.98, 1.0] 0.012

During the follow-up period (1.1.1998 — 31.12.2019), 165 out of 582 males with M13_MUSCLEATROPH died.

Mortality risk

Mortality risk for people of age

years, who have M13_MUSCLEATROPH.

N-year risk Females Males
1 0.222% 0.409%
5 1.237% 2.655%
10 3.025% 6.217%
15 5.429% 11.554%
20 9.286% 19.826%

Relationships between endpoints

↥

Index endpoint: M13_MUSCLEATROPH – Muscle wasting and atrophy, not elsewhere classified

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data